Royalty Report: Drugs, Cancer, Biotechnology – Collection: 26749


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Delivery
  • Drug Discovery
  • Therapeutic
  • Genome
  • DNA
  • HIV / AIDs
  • Antibody
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26749

License Grant
The University hereby grants to Licensee, under the Licensed Patents and other intellectual property rights of The University, subject to all the terms and conditions of this Agreement, a non-transferable worldwide exclusive license for the term defined by Article III to make, have made, use, sell and practice the Invention.
License Property
The University has  produced an invention entitled Novel Vectors for Gene Delivery and Therapy (OCR 722) and Specific Vectors in Gene Delivery to HIV+ Cells (OCR 721) and Vectors for the Diagnosis and Treatment of Solid Tumors Including Melanoma, U.S. Patent Application no. 08/486,422 (the INVENTION).  This invention focuses on the design of vectors for specific delivery of genes to human immunodeficiency virus (HIV)-infected cells.
Field of Use
We have recently demonstrated that certain bacterial and protozoan organisms, e.g. Salmonella typhymurium, Leishmania amazonensis, and Mycobacterium avium exhibit invasion preference for human melanoma or colon carcinoma cells over normal human melanocytes and colon epithelium in culture.  Further, mutants of Salmonella typhymurium were isolated showing enhanced specificity for melanoma and colon carcinoma cells over that already shown by the wild type parental strain.  One such superinfective, tumor-specific mutant was further transfected with a Herpes simplex thymidine kinase gene that was able to convert the non-toxic prodrug, ganciclovir, to its toxic phosphorylated form when the Salmonella was infected into melanoma tumors, thus reducing the size of the tumors. The current invention uses similar technology to isolate mutants of Salmonella typhimurium or other suitable vectors that show specific invasion preference for HIV+ cells.  Once isolated, such mutants are subjected to further genetic modifications to express and secrete suicide gene products into the cytoplasm of the HIV+ cells.  Targets for the suicide gene products include both the HIV-infected cells and/or the AIDS virus itself.

IPSCIO Record ID: 29247

License Grant
The Licensor granted an exclusive license to the patent, Tumor Radiosensitization Using Gene Therapy, for the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.
Field of Use
'Field' shall mean the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.

IPSCIO Record ID: 367305

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patents and Licensed Technology to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Territory and in the Field of Use only.
License Property
Licensor owns one hundred percent interest in the Human Gene Therapy Research Institute located in Des Moines, Iowa.

Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.

The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
ATM Vector;
Dual adenoviral delivery of transgenes.

The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.

Field of Use
HyperAcute immunotherapies are designed to break tolerance and enable longer duration of anti-tumor effect.  HyperAcute immunotherapy technology has a wide range of anti-cancer applications including two additional product candidates, HyperAcute Lung and HyperAcute Melanoma, in active clinical development.  HyperAcute immunotherapy technology is designed to fight cancer by activating the human body's naturally protective and rapid immune response to the a-Gal carbohydrate.  HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which a-Gal is present by activating complement, an important component of the immune system that is capable of cell destruction. After destruction, we believe the resulting cellular fragments bound by anti-a-Gal antibodies are processed by the immune system to elicit an enhanced multi-faceted immune response to tumor-associated antigens common to both the immunotherapy and the patient's tumor cells.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

IPSCIO Record ID: 294014

License Grant
Licensor, a medical research centers, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
The patents and patent applications relate to Modified Adena-Associated Virus Vector Capable of Expression from a Novel Promoter.

Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.

Field of Use
The field of use is the development of compositions and methods utilizing Adeno-Associated Viral Vectors embodied in the Licensed Patent Rights which are useful in the treatment and prophylaxis of human and animal diseases, and does not include compositions and methods for the treatment and prophylaxis of cystic fibrosis.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.

IPSCIO Record ID: 256218

License Grant
The Licensor of Israel grants an exclusive, worldwide royalty bearing license, with the right to grant sublicenses through multiple tiers,  under the Licensed IP Rights to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, import, export, commercialize and otherwise exploit Licensed Products for use in the Field.
License Property
The licensed patents refer to Chimeric Receptor Genes and Cells Transformed Therewith.

Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al

Eshhar-NIH patent US 8,211,422, Eshhar et al

Eshhar-NIH pending application [US 13/281,560, Eshhar et al

KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.

Field of Use
The Field shall mean, collectively, all oncology applications and all other applications, as mutually agreed in writing by the parties and attached as an amendment to this Agreement.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 1617

License Grant
The Company obtains an exclusive worldwide license to the Licensed Patents, probasin gene (PG) and to practice, use or sell the Licensed Processes from Canadian University.
License Property
Licensed Patents shall mean all patent applications respecting PG (a) International PCT Application Serial No. PCT CA 9300319 filed August 9, 1993 entitled DNA Sequences of Rat Probasin Gene; and (b) all patent applications respecting PG which may be filed from time to time by University pursuant to this Agreement.
Field of Use
Field of Use shall mean human gene therapy involving the transfer of genetic material into target mammalian cells in vitro or in vivo for the purpose of intercellular drug delivery and/or treatment of a disease or medical condition.

IPSCIO Record ID: 356951

License Grant
The University grants, to the extent of the Licensed Territory, a non-exclusive right and license to use University Technology in the Licensed Field, with the right to sublicense, provided that each such sublicense is granted concurrently with the grant of a license to Patent Rights, if any.

The University grants, to the extent of the Licensed Territory, an exclusive license under the Patent Rights to make, have made, use, offer for sale, sell and import Licensed Products in the Licensed Field, with the right to sublicense.

License Property
The University owns and controls valuable inventions known as Identification of the gene for vitamin K epoxide reduclase, Production of a peptide useful for the isolation of the vitamin-K carboxylase and, Human factor IX variants with an extended half life, collectively the inventions.
Field of Use
The Licensed Field means, and is limited to, the practice of the Inventions for the production of Factors IX and VII including without limitation all cleavage products and mutants thereof, for therapeutic use.

Licensee focuses on providing novel oncology and hematology therapeutics.

IPSCIO Record ID: 41918

License Grant
The parties entered into a non-exclusive patent license agreement for certain patents related to AAV1 Vector gene delivery systems.
License Property
The Licensor is dedicated to developing novel antibacterial therapies called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.

Adeno-Associated Virus (AAV) is a non-enveloped, single stranded DNA virus that can infect both nondividing and dividing cells. AAV is thought to be non-pathogenic to humans and only replicates in the presence of a helper virus. These features have made AAV a useful tool for gene delivery to a wide variety of cell types and an attractive vector for gene therapy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.